News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rib-X Pharmaceuticals, Inc. Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients With Acute Bacterial Skin and Skin Structure Infections


5/14/2013 9:58:00 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., today announced the initiation of a Phase 3 clinical trial evaluating delafloxacin, the company’s lead antibiotic, in patients with acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin is a novel fluoroquinolone antibiotic with intravenous (IV) and oral formulations that have demonstrated a favorable safety and efficacy profile in prior studies against infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and a broad array of Gram-positive and Gram-negative bacteria, many of which were resistant to other quinolones.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES